MetaCap

ACADIA Pharmaceuticals (ACAD) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xeris Biopharma (XERS) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 148.5% versus a loss of 27.4%. Over five years, XERS leads with a +682.0% price change compared with -8.9% for ACAD. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $2.96 billion), about 1.0 times the size.

On valuation, ACADIA Pharmaceuticals trades at a lower forward P/E (15.8x vs 63.6x for Xeris Biopharma). ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus 0.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACAD-27.38%XERS+148.46%
+158%+59%-39%
Nov 21, 20251 yearNov 20, 2026
ACAD-10.65%XERS+647.58%
+683%+297%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACAD versus XERS key metrics
MetricACADXERS
Share price$17.11$16.97
Market cap$2.96B$3.10B
1-day change-2.73%+2.11%
YTD return-35.94%+116.18%
1-year return-27.38%+148.46%
5-year return-8.94%+682.03%
P/E ratio (TTM)8.07—
Forward P/E15.7563.64
EPS (TTM)$2.12$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.07B$291.85M
Revenue growth (YoY)+11.87%+43.72%
Net income (latest FY)$391.00M$554.00K
Gross margin91.69%85.41%
Operating margin9.78%8.53%
Net margin36.49%0.19%
52-week high$30.96$17.28
52-week low$15.86$5.25
Distance from 52-week high-44.74%-1.79%
Analyst consensusbuystrong_buy
Avg. price target upside+77.21%+1.89%
Average volume2.18M2.86M
Shares outstanding172.83M182.70M
Employees796435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XERS has outperformed ACAD by 175.8 percentage points over the past year.
  • ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus 0.2 cents for Xeris Biopharma.
  • Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs +11.87%).

About ACADIA Pharmaceuticals

ACAD stock →

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

ACAD vs XERS FAQ

Which is bigger, ACADIA Pharmaceuticals or Xeris Biopharma?

Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $2.96B for ACADIA Pharmaceuticals (ACAD).

Which stock has performed better over the past year, ACAD or XERS?

XERS returned +148.46% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.

Are ACADIA Pharmaceuticals and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons